Evidence map›Paper›PMID 36964844›Full record

ArticleAnnals of surgical oncology2023

Hospital Designations and Their Impact on Guideline-Concordant Care and Survival in Pancreatic Cancer. Do They Matter?

Gilbert Z Murimwa, John D Karalis, Jennie Meier, Jingsheng Yan, Hong Zhu, Caitlin A Hester, Matthew R Porembka, Sam C Wang, John C Mansour, Herbert J Zeh and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Gilbert Z MurimwaDivision of Surgical Oncology, Department of Surgery, University of Texas Southwestern, Dallas, TX, USA.
John D KaralisDivision of Surgical Oncology, Department of Surgery, University of Texas Southwestern, Dallas, TX, USA.
Jennie MeierDivision of Surgical Oncology, Department of Surgery, University of Texas Southwestern, Dallas, TX, USA.
Jingsheng YanDepartment of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Hong ZhuDepartment of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Caitlin A HesterDivision of Surgical Oncology, Department of Surgery, University of Miami, Miami, FL, USA.
Matthew R PorembkaDivision of Surgical Oncology, Department of Surgery, University of Texas Southwestern, Dallas, TX, USA.
Sam C WangDivision of Surgical Oncology, Department of Surgery, University of Texas Southwestern, Dallas, TX, USA.
John C MansourDivision of Surgical Oncology, Department of Surgery, University of Texas Southwestern, Dallas, TX, USA.
Herbert J ZehDivision of Surgical Oncology, Department of Surgery, University of Texas Southwestern, Dallas, TX, USA.
Adam C YoppDivision of Surgical Oncology, Department of Surgery, University of Texas Southwestern, Dallas, TX, USA.
Patricio M PolancoDivision of Surgical Oncology, Department of Surgery, University of Texas Southwestern, Dallas, TX, USA. patricio.polanco@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USUniversity of Miami · US

Funding

Targeted inhibition in stromal TGFβ activity in pancreatic cancerR01CA243577 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI BREKKEN, ROLF A · 2020 to 2023
$1.7M
NCI NIH HHS 3R01CA243577-02S1
6 · The paper itself

Abstract

backgroundPancreatic ductal adenocarcinoma (PDAC) requires complex multidisciplinary care. European evidence suggests potential benefit from regionalization, however, data characterizing the ideal setting in the United States are sparse. Our study compares the significance of four hospital designations on guideline-concordant care (GCC) and overall survival (OS). PATIENTS AND

methodsThe Texas Cancer Registry was queried for 17,071 patients with PDAC treated between 2004 and 2015. Clinical data were correlated with hospital designations: NCI designated (NCI), high volume (HV), safety net (SNH), and American College of Surgeons Commission on Cancer accredited (ACS). Univariable (UVA) and multivariable (MVA) logistic regression were used to assess associations with GCC [on the basis of National Comprehensive Cancer Network (NCCN) recommendations]. Cox regression analysis assessed survival.

resultsOnly 43% of patients received GCC. NCI had the largest associated risk reduction (HR 0.61, CI 0.58-0.65), followed by HV (HR 0.87, CI 0.83-0.90) and ACS (HR 0.91, CI 0.87-0.95). GCC was associated with a survival benefit in the full (HR 0.75, CI 0.69-0.81) and resected cohort (HR 0.74, CI 0.68-0.80). NCI (OR 1.52, CI 1.37-1.70), HV (OR 1.14, CI 1.05-1.23), and SNH (OR 0.78, CI 0.68-0.91) all correlated with receipt of GCC. For resected patients, ACS (OR 0.63, CI 0.50-0.79) and SNH (OR 0.50, CI 0.33-0.75) correlate with GCC.

conclusionsA total of 43% of patients received GCC. Treatment at NCI and HV correlated with improved GCC and survival. Including GCC as a metric in accreditation standards could impact survival for patients with PDAC.

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsHospitalsHumansTexasUnited States

Identifiers

PMID36964844
OpenAlexW4360942185

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.